198 related articles for article (PubMed ID: 25151742)
1. [Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters].
Ling J; Qian LX; Ding JJ; Jiao Z
Yao Xue Xue Bao; 2014 May; 49(5):686-94. PubMed ID: 25151742
[TBL] [Abstract][Full Text] [Related]
2. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.
Staatz CE; Willis C; Taylor PJ; Lynch SV; Tett SE
Liver Transpl; 2003 Feb; 9(2):130-7. PubMed ID: 12548506
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.
Staatz CE; Willis C; Taylor PJ; Tett SE
Clin Pharmacol Ther; 2002 Dec; 72(6):660-9. PubMed ID: 12496747
[TBL] [Abstract][Full Text] [Related]
6. [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].
Zuo XC; Yuan H; Zhang BK; Ng CM; Barrett JS; Yang GP; Huang ZJ; Pei Q; Guo R; Zhou YN; Jing NN; Di W
Yao Xue Xue Bao; 2012 Jul; 47(7):941-6. PubMed ID: 22993862
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
.
Wang X; Han Y; Chen C; Ma L; Xiao H; Zhou Y; Cui Y; Wang F; Su B; Yao Y; Ding J
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):125-134. PubMed ID: 30663980
[TBL] [Abstract][Full Text] [Related]
8. Considerations in analyzing single-trough concentrations using mixed-effects modeling.
Booth BP; Gobburu JV
J Clin Pharmacol; 2003 Dec; 43(12):1307-15. PubMed ID: 14615466
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
10. [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].
Ding JJ; Jiao Z; Wang Y
Yao Xue Xue Bao; 2011 Dec; 46(12):1493-500. PubMed ID: 22375425
[TBL] [Abstract][Full Text] [Related]
11. [Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant].
Xue L; Rui JZ; Zhang Y; Miao LY
Yao Xue Xue Bao; 2009 Oct; 44(10):1145-51. PubMed ID: 20055140
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
[TBL] [Abstract][Full Text] [Related]
13. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
[TBL] [Abstract][Full Text] [Related]
14. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model.
Gibiansky L; Gibiansky E; Bauer R
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):17-35. PubMed ID: 22101761
[TBL] [Abstract][Full Text] [Related]
16. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.
Antignac M; Hulot JS; Boleslawski E; Hannoun L; Touitou Y; Farinotti R; Lechat P; Urien S
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):409-16. PubMed ID: 15991041
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients.
Jacobson P; Ng J; Ratanatharathorn V; Uberti J; Brundage RC
Bone Marrow Transplant; 2001 Oct; 28(8):753-8. PubMed ID: 11781626
[TBL] [Abstract][Full Text] [Related]
19. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method.
Wang J; Liang WQ; Wu JJ; Pan CM
Acta Pharmacol Sin; 2000 Oct; 21(10):954-60. PubMed ID: 11501052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
